Last Updated : May 9, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
TBC | cabotegravir | HIV-1 infection, pre-exposure prophylaxis | Active | |||
TBC | momelotinib | Myelofibrosis | Pending | |||
TBC | avapritinib | Advanced Systemic Mastocytosis | Active | |||
TBC | zilucoplan | Generalized myasthenia gravis (gMG) | Suspended | |||
TBD | Cabozantinib | Withdrawn | ||||
TBD | Entrectinib | Withdrawn | ||||
TBD | Bevacizumab | Cancelled | ||||
TBD | Rituximab | Cancelled | ||||
TBD | Trastuzumab | Cancelled | ||||
Tecartus | brexucabtagene autoleucel | Mantle cell lymphoma | Reimburse with clinical criteria and/or conditions | Complete |